FinGraph AI values Boston Scientific Corporation with a deterministic 3-stage discounted cash flow (DCF) model built from BSX's SEC 10-K/10-Q filings and live market data — then cross-checks it against peer multiples, forensic-accounting scores and a reverse-DCF. Run the full report in under a minute.
Run the live BSX report →A 3-stage unlevered DCF with a CAPM/WACC build-up, compared directly to BSX's market price so you can see the premium or discount to the baseline.
The growth rate the market is currently pricing into Boston Scientific Corporation, measured against its real historical performance.
Altman Z (distress), Piotroski F (fundamental strength) and Beneish M (earnings-manipulation) scores from the filings.
Boston Scientific Corporation benchmarked on P/E, EV/EBITDA, P/S and margins against a live comparable-company set.
Boston Scientific Corporation (NYSE: BSX) is covered in FinGraph AI's Healthcare universe. Every figure in the report traces to BSX's SEC EDGAR filings and live market data — there are no hand-entered numbers, and the DCF is deterministic rather than LLM-estimated. This page is informational and updates when you run the live report.
Value BSX now →Informational research only — not investment advice, and not a recommendation to buy or sell any security. FinGraph AI is not a registered investment adviser. Figures derive from SEC EDGAR filings and market data and may differ from other sources.